Dr. Reddy's and MediCane launch medical cannabis products in Germany
Germany forms more than half of the EU’s medical cannabis market
Dr. Reddy's Laboratories and MediCane Health have joined forces to launch medical cannabis products in Germany.
As part of the collaboration, which began last year, MediCane will supply the medical cannabis products to Dr. Reddy's from its EU-GMP-certified facilities in Portugal along with providing logistical and regulatory support. Dr. Reddy’s will be the exclusive distributor of the products in Germany.
The launch marks MediCane’s entry into the pharmaceutical sector of a major European market, while reinforcing Dr. Reddy's presence in Germany’s growing medical cannabis market. This comes after Dr. Reddy's recent acquisition of Nimbus Health GmbH, which specializes in the distribution, registration, sales and marketing of medical cannabis.
Medical cannabis was legalised in Germany in 2017 and the country now represents more than half of the European Union medical cannabis market, in large part due to developed regulations and reimbursement from sick funds under certain circumstances. According to market intelligence firm Prohibition Partners, insurance companies reimbursed around 60% of medical cannabis prescriptions in 2019.
The demand for medical cannabis has been increasing over recent years and the market in Germany is now valued at €122 million with 25% growth between 2020 and 2021. Around 150,000 German patients use medical cannabis to supplement treatment of a wide range of conditions. It is particularly popular for pain management, spasticity, anorexia, vomiting and depression.
Dr. Reddy's and MediCane have also signed an agreement for the co-funding of a Phase II clinical trial for a cannabis product aimed at symptom relief of Behavioral and Psychological Symptoms of Dementia (BPSD). BPSD refers to the spectrum of commonly observed non-cognitive and non-neurological symptoms of dementia, such as agitation, aggression, psychosis, depression, and apathy.
Dr. Reddy's will hold exclusive sales and marketing rights for the product in Europe (except Russia and CIS countries) upon completion of the trial, which is expected to begin during the second half of 2022.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance